This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 6–8, 2023 | Munich, GermanyNovember 14–15, 2023 | Digital Partnering

One-carbon Therapeutics AB


One-carbon therapeutics AB focuses on late-stage pre-clinical development of its primary clinical drug candidate targeting MTHFD1/2 proteins regulating cancer DNA damage response and metabolism. We are scaling up for the Phase I trial expected to start during 2024. Our inhibitor is a small molecule developed for multiple oncology indications and represents a novel approach to target validated cancer vulnerabilities. We focus on KRAS-mutated solid tumors and hematological cancers based on a biomarker approach. We also plan for multiple combinations with DDR profile